The authors reply:
Letter on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Clark et al.

Abstract

However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass. Obviously, CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/volume and more recently amount and distribution of intra- and intermuscular adipose tissue. Also individual muscles can be assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difficult because DXA and QCT/MRI measure different physical parameters.

We very much appreciate your valuable comments and your interest in the topic raised in our paper. One of your main concerns seem to be the statement at the end of our contribution suggesting that ‘DXA is the gold standard for the measurement of muscle mass’. Perhaps the term ‘gold’ could have been omitted. However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass as concluded in the discussion and summarized in the abstract. Obviously, CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/volume and more recently amount and distribution of intramuscular and intermuscular adipose tissue. Also, individual muscles can be assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difficult because DXA and QCT/MRI measure different physical parameters.

As you correctly describe, primary outcome of DXA is lean mass in g, of CT is muscle volume in cm³ or area in cm² and CT density in Hounsfield units [HU] and of MRI is also muscle volume in cm³ or area and proton density fat and water fraction in % when using advanced Dixon sequences. None of the three techniques measures muscle mass in g or muscle density in g/cm³. CT and MRI do not even directly measure a mass in g. Thus, from a physics point of view, none can serve as a gold standard for any of the other two methods, with the exception of volume/area measurements of CT and MRI.

For the further discussion, it is important to remember that all current definitions of sarcopenia include appendicular lean mass but not muscle area/volume. You refer to accuracy validation studies with MR and CT but all evaluated area, not mass. Correlations reported between DXA lean mass and CT muscle area in the thigh were moderate in young subjects (r² = 0.74) and even lower in premenopausal lean and obese women (r² = 0.59 and r² = 0.58, respectively), thus a substitution of DXA by CT in the definition of sarcopenia, i.e. of mass by volume, will be problematic.

There are indeed some studies that report muscle mass from CT and MRI scans. In these studies, muscle mass has been estimated by multiplying measured muscle volume with a density of 1.06 or 1.04 g/cm³, values based on publications summarized in the ICRP reference man report from 1972. In this report, the proportion of fat of wet skeletal muscle in adults is given as a range from 2.2% to 9.4%. Thus, accuracy of assuming a muscle density of 1.06 or 1.04 g/cm³ is questionable if higher degrees of muscle fat infiltration occur, because higher proportions of fat will decrease density. Correlation coefficients of r² ≥ 0.96 have been reported in young and elderly healthy volunteers between muscle mass in the thigh estimated with CT and fat free mass (FFM) measured by DXA but results are likely to change in subjects with a higher amount of intramuscular adipose tissue of let’s say greater than 10%. Thus, these studies for a specific population serve more as a validation of the simplifying assumptions made to obtain CT/MRI muscle mass than a validation for DXA.

Finally, you point out only moderate correlations between longitudinal changes in lean mass and muscle volume. But with the current definitions of sarcopenia,
wouldn’t this be an argument in favour of DXA? One could criticize that definitions of sarcopenia inherently favour DXA and should have been better tailored towards CT or MR measurements in the first place. They even use appendicular lean instead of muscle mass, which has been rightfully criticized. However, the real problem is the rather poor correlation of the common DXA/CT/MRI measurements with function, which has caused the integration of functional measurements in the definitions of sarcopenia. Thus, we do not imply that DXA will be the gold standard for the diagnosis of sarcopenia, which requires a functional component. However, DXA can serve as a reference standard for lean mass, considering the limitations described in our article. Similar to osteoporosis, DXA may become the workhorse in clinical routine of sarcopenia. CT and MRI should be regarded as a complementary more powerful imaging method to DXA that may improve our understanding on intervention and may eventually better explain effects on functional muscle outcome than simple lean mass or area/volume measurements.

**Acknowledgement**

The authors certify that they comply with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.

Fanny Buckinx  
Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

Francesco Landi  
Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart Rome, Milan, Italy

Matteo Cesari  
Gérontopôle, University Hospital of Toulouse, Toulouse, France  
INSERM UMR1027, University of Toulouse III Paul Sabatier, Toulouse, France

Roger A. Fieding  
Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

Marjolein Visser  
Department of Health Sciences, VU University Amsterdam, Amsterdam, Netherlands  
Department of Nutrition and Dietetics, VU University Medical Center, Amsterdam, Netherlands

Klaus Engelke  
Institute of Medical Physics, University of Erlangen, Erlangen, Germany

Stefania Maggi  
National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy

Elaine Dennison  
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

Nasser M. Al-Daghri  
Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

Sophie Allepaerts  
Department of Geriatrics, CHU-Liège, Liège, Belgium

Jurgen Bauer  
Department of Geriatric Medicine, Klinikum, Carl von Ossietzky University, Oldenburg, Germany

Ivan Bautmans  
Gerontology and Frailty in Ageing Research Department, Vrije Universiteit Brussel (VUB), Brussels, Belgium

Maria-Luisa Brandi  
Department of Surgery and Translational Medicine, University of Florence, Florence 59139, Italy

Olivier Bruyère  
Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

Tommy Cederholm  
Human Medicines Research and Development Support Division, Scientific Advice, London, UK

Francesca Cerreta  
Human Medicines Research and Development Support Division, Scientific Advice, London, UK

Antonio Cherubini  
Geriatrics and Geriatric Emergency Care, IRCCS-INRCA, Ancona, Italy

Cyrus Cooper  
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK  
NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK

Alphonso Cruz-Jentoft  
Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (Irycis), Madrid, Spain

Eugene McCloskey  
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK  
MRC and Arthritis Research UK Centre for Integrated research in Musculoskeletal Ageing (CIMA), London, UK
Bess Dawson-Hughes  
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

Jean-Marc Kaufman  
Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Ghent, Belgium

Andrea Laslop  
Scientific Office, Austrian Agency for Health and Food Safety, Vienna, Austria

Jean Petermans  
Department of Geriatrics, CHU-Liège, Liège, Belgium

Jean-Yves Reginster  
Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

René Rizzoli  
Service of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Sian Robinson  
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital, Southampton NHS Foundation Trust, Southampton, UK

Yves Rolland  
Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse (CHU Toulouse); UMR INSERM 1027, University of Toulouse III, Toulouse, France

Ricardo Rueda  
Abbott Nutrition R&D, Granada, Spain

Bruno Vellas  
Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse (CHU Toulouse); UMR INSERM 1027, University of Toulouse III, Toulouse, France

John A. Kanis  
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK Institute of Health and Ageing, Australian Catholic University, Melbourne, Australia

References


DOI: 10.1002/jcsm.12387